| scholarly article | Q13442814 |
| P50 | author | Karl Eugen Ruckhäberle | Q100415175 |
| Michael Untch | Q38292680 | ||
| P2093 | author name string | Nadia Harbeck | |
| Volkmar Müller | |||
| Johannes Ettl | |||
| Christoph Thomssen | |||
| Lothar Müller | |||
| Diana Lüftner | |||
| Renate Haidinger | |||
| Susanne Briest | |||
| Rachel Wuerstlein | |||
| Doris Augustin | |||
| Norbert Marschner | |||
| P2860 | cites work | Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients | Q43648274 |
| Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. | Q45044547 | ||
| Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial | Q45073151 | ||
| ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3). | Q47293093 | ||
| AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2017. | Q53737037 | ||
| Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. | Q54113079 | ||
| New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. | Q55033068 | ||
| AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2017. | Q55617888 | ||
| Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results | Q88385844 | ||
| Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer | Q29620676 | ||
| 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). | Q30313649 | ||
| ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). | Q30317064 | ||
| Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases | Q35653866 | ||
| Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial | Q36935214 | ||
| Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2. | Q37534910 | ||
| 1st International consensus guidelines for advanced breast cancer (ABC 1). | Q37994463 | ||
| Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial | Q38373098 | ||
| Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer | Q38743961 | ||
| Palbociclib and Letrozole in Advanced Breast Cancer | Q39105459 | ||
| Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind | Q39944735 | ||
| Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. | Q40446127 | ||
| Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study | Q43522608 | ||
| Breast cancer brain metastases responding to primary systemic therapy with T-DM1. | Q43621364 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 48-58 | |
| P577 | publication date | 2018-03-01 | |
| P1433 | published in | Breast Care | Q15764648 |
| P1476 | title | ABC4 Consensus: Assessment by a German Group of Experts | |
| P478 | volume | 13 |
| Q91709281 | The impact of systemic precision medicine and immunotherapy treatments on brain metastases | cites work | P2860 |
Search more.